Science Driving IO Dealmaking Panel

Session details:

As the immuno-oncology landscape continues to evolve, scientific innovation is increasingly shaping how partnerships are formed, assets are evaluated, and investment decisions are made. This panel will explore the scientific advances driving today's dealmaking activity, the characteristics that distinguish high-value programs, and how emerging biology is influencing licensing, acquisitions, and strategic collaborations across the field.